Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 6/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PER2 | O15055 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22017739 | 0.85 | PER2 (0.37) | PIK3CDPER2CRY2 | |
| SCHEMBL22017935 | 0.82 | GAA (0.39) | PIK3CDPOLBPER2CRY2L3MBTL1 | |
| SCHEMBL10121114 | 0.82 | PER2 (0.50) | PIK3CDPOLBPER2HDAC1CRY2 | |
| SCHEMBL22017463 | 0.80 | ALDH1A1 (0.37) | PIK3CDPER2P2RX7L3MBTL1 | |
| SCHEMBL12545892 | 0.79 | PIK3CD (0.48) | PIK3CDPOLBHDAC1PARP1P2RX7 | |
| SCHEMBL22017464 | 0.78 | L3MBTL1 (0.34) | POLBPER2CRY2L3MBTL1 | |
| SCHEMBL22017742 | 0.77 | CYP2D6 (0.36) | POLBPER2CRY2L3MBTL1 | |
| SCHEMBL22017743 | 0.77 | PER2 (0.32) | PER2 | |
| SCHEMBL22017468 | 0.77 | PER2 (0.38) | PER2CRY2 | |
| SCHEMBL22017937 | 0.76 | HRH3 (0.39) | PIK3CDPER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332485-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210198288-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2021-07-01 | — | — | US | disclosed |
| US-20200157123-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157123-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | PIK3CD 4344/4885POLB 2001/4885PER2 3231/4885 |
| US-20210198288-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | PIK3CD 4344/4885POLB 2001/4885PER2 3231/4885 |
| US-11332485-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | PIK3CD 4344/4885POLB 2001/4885PER2 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.